V
0.707
0.06 (9.01%)
| Previous Close | 0.648 |
| Open | 0.659 |
| Volume | 484,602 |
| Avg. Volume (3M) | 416,722 |
| Market Cap | 65,363,392 |
| Price / Sales | 6.29 |
| Price / Book | 238.54 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -236.41% |
| Diluted EPS (TTM) | -1.14 |
| Quarterly Revenue Growth (YOY) | -10.10% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | -53.66 M |
| Levered Free Cash Flow (TTM) | -32.56 M |
| Return on Assets (TTM) | -62.87% |
| Return on Equity (TTM) | -1,546.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Verrica Pharmaceuticals Inc. | Mixed | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 44.37% |
| % Held by Institutions | 31.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caligan Partners Lp | 31 Mar 2025 | 8,992,954 |
| Sovran Advisors, Llc | 31 Mar 2025 | 392,163 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jul 2025 | Announcement | Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 |
| 01 Jul 2025 | Announcement | Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts |
| 28 May 2025 | Announcement | Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York |
| 13 May 2025 | Announcement | Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results |
| 07 May 2025 | Announcement | Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 |
| 30 Apr 2025 | Announcement | Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |